Jilin Sichang Pharmaceutical

Jilin Sichang Pharmaceutical is a joint venture between Sihuan Pharmaceutical Group and Shandong Buchang Pharmaceutical, established in 2009 and based in Meihekou City, Jilin Province. The company specializes in the research, development, production, and sales of both chemical and traditional Chinese medicine (TCM) products, with a strong focus on cardiovascular and cerebrovascular (CCV) treatments. Its core product portfolio includes Tanshinone IIA sodium sulfonate injection, Tiopronin, and Monoammonium Glycyrrhizinate S, which are used to treat heart conditions and liver disorders. Operating multiple GMP-certified production lines for small and large volume injections and active pharmaceutical ingredients (APIs), the company serves as a key manufacturing hub for its parent groups. Jilin Sichang has been recognized as a national high-tech enterprise and a Specialized, Special and New enterprise in Jilin Province.